YM BioSciences

ymbiosciences.com

YM BioSciences Inc.

5045 Orbitor Drive; Building 11, Suite 400
L4W 4Y4 Mississauga
Canada

Phone

ymbiosciences.com
Contact
Profile Products News

About YM BioSciences

YM BioSciences Inc. is a company that identifies, develops and commercializes differentiated products principally in the area of oncology for patients worldwide.

Read more about YM BioSciences

Advertisement

Revolutionize your production: real-time Raman analysis for maximum efficiency
Revolutionize your production: real-time Raman analysis for maximum efficiency
Efficient inline analysis for liquids and solids
Efficient inline analysis for liquids and solids
User-friendly software for effortless Design of Experiments (DoE)
User-friendly software for effortless Design of Experiments (DoE)

Product portfolio of YM BioSciences

Product portfolio

Show all

News about YM BioSciences

YM BioSciences

12-Aug-2010 | research and development

YM BioSciences granted Orphan Drug Designation for CYT387

JAK1/2 inhibitor currently in Phase II clinical study in myelofibrosis

Read news
YM BioSciences

07-Jun-2010 | people

YM BioSciences appoints Dr. Nick Glover as President and Chief Operating Officer

YM BioSciences Inc. announced the appointment of Dr. Nick Glover to the newly created position of President and Chief Operating Officer. Dr. Glover will ...

Read news
YM BioSciences

31-May-2010 | research and development

YM BioSciences enrolls first US patient in Phase II randomized, double-blind brain metastases trial for nimotuzumab

YM BioSciences Inc. announced that the first US patient has been enrolled in its randomized, double-blind trial evaluating nimotuzumab in patients with ...

Read news
YM BioSciences

21-Apr-2010 | research and development

YM BioSciences announces pivotal preclinical efficacy data for the JAK1/2 inhibitor CYT387 published

YM BioSciences Inc. announced the pre-publication of pivotal preclinical data for CYT387, the company's highly selective and potent JAK1/2 inhibitor, ...

Read news
YM BioSciences

01-Apr-2010 | research and development

YM BioSciences announces early expansion of ongoing CYT387 Phase I/II clinical study based on favorable safety and activity data

YM BioSciences Inc. announced that it has received ethics board approval to expand enrolment in its Phase I/II clinical trial of CYT387 at Mayo Clinic in ...

Read news
YM BioSciences

12-Feb-2010 | research and development

YM Biosciences granted two US patents for AeroLEF

YM BioSciences Inc. announced that it has been granted two additional patents in the US for AeroLEF®, the Company’s proprietary, inhaled-delivery ...

Read news
YM BioSciences

03-Feb-2010 | business & finance

YM BioSciences completes merger with Cytopia

YM BioSciences Inc. announced that the merger of Cytopia Limited into YM under a Scheme of Arrangement, has been concluded. "With the completion of this ...

Read news
YM BioSciences

13-Jan-2010 | research and development

YM BioSciences announces collaboration with University of Toronto focused on development of radionuclide-conjugated antibodIes

YM BioSciences Inc. announced results of a collaboration with researchers at the University of Toronto for the development of highly potent antibody- ...

Read news
Show more news about YM BioSciences

Here you will find YM BioSciences Inc.